Categories: Technology

Nokia Corporation – Managers’ transactions (Fisk)

 | Source: Nokia Oyj

Nokia Corporation
Managers’ transactions
20 February 2026 at 16:00 EET

Nokia Corporation – Managers’ transactions (Fisk)

Transaction notification under Article 19 of EU Market Abuse Regulation.
____________________________________________
Person subject to the notification requirement
Name: Fisk, Louise
Position: Other senior manager

Issuer: Nokia Corporation
LEI: 549300A0JPRWG1KI7U06
Notification type: INITIAL NOTIFICATION
Reference number: 144065/5/4
____________________________________________

Transaction date: 2026-02-19
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009000681
Nature of the transaction: ACQUISITION

Transaction details
(1): Volume: 174 Unit price: 6.3015

Aggregated transactions
(1): Volume: 174 Volume weighted average price: 6.3015

About Nokia
Nokia is a global leader in connectivity for the AI era. With expertise across fixed, mobile, and transport networks, we’re advancing connectivity to secure a brighter world.

Inquiries:

Nokia Communications
Phone: +358 10 448 4900
Email: press.services@nokia.com
Maria Vaismaa, Vice President, Corporate Communications

Nokia
Investor Relations
Phone: +358 931 580 507
Email: investor.relations@nokia.com

GlobeNews Wire

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

41 minutes ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

41 minutes ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

42 minutes ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

42 minutes ago